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Cardiovascular toxicity is unfortunately a potential short- or long-term sequela of breast
cancer therapy. Both conventional chemotherapeutic agents such as anthracyclines and
newer targeted agents such as trastuzumab can cause varying degrees of cardiac dys-
function. Type I cardiac toxicity is dose-dependent and irreversible, whereas Type II is not
dose-dependent and is generally reversible with cessation of the drug. In this review, we
discuss what is currently known about the cardiovascular effects of systemic breast cancer
treatments, with a focus on the putative mechanisms of toxicity, the role of biomarkers,
and potential methods of preventing and minimizing cardiovascular complications.
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INTRODUCTION
Breast cancer remains the most common cancer among women.
It is estimated that more than 3.1 million women with a history of
invasive breast cancer are alive in the United States. By 2024, that
number is estimated to increase to 3.9 million (1). Advances in
breast cancer treatments have fortunately led to improvements in
survival. However, with more women living longer, delayed tox-
icities of therapy have become more significant. Cardiovascular
complications from therapy can occur to varying degrees and, in
severe cases, can have devastating consequences.
Cardiotoxicity from breast cancer therapy is seen most com-
monly after treatment with anthracyclines and trastuzumab, at
times necessitating discontinuation of otherwise effective treat-
ment. Yet despite the large number of studies that have addressed
the cardiotoxic effects from breast cancer therapy, few guidelines
exist for the detection, monitoring, and management of patients
with treatment-related cardiotoxicity.
Cardio-oncology has emerged as a new field that focuses on
preserving cardiovascular health in cancer patients. Key areas of
research include understanding the mechanisms of cardiac dys-
function, developing biomarkers for early detection, and institut-
ing appropriate therapy for both the prevention and treatment of
cardiac toxicity.
ANTHRACYCLINE-INDUCED CARDIOTOXICITY
The role of anthracyclines in the treatment of breast cancer is
well-established (2, 3). However, the benefit of this class of drugs
is often limited by the risk of myocardial damage which, in severe
cases, can progress to symptomatic congestive heart failure (CHF).
Anthracycline-induced cardiotoxicity can take on a variety of
forms. Acute cardiotoxicity is relatively uncommon and is usually
not life threatening. It can manifest as electrocardiogram changes,
arrhythmias, and transient depression of myocardial contractility.
These changes generally occur during intravenous administration
and normally resolve on their own with discontinuation of the
drug (4–6). Chronic anthracycline-induced cardiotoxicity, on the
other hand, is more common and of much greater clinical concern.
This type of cardiotoxicity is classified as Type I and is dose-related,
progressive and irreversible.
Chronic cardiotoxicity typically presents within 1 year of treat-
ment but late manifestations can occur up to 10 or more years
following anthracycline therapy (7). Asymptomatic diastolic dys-
function may be an early finding in patients exposed to anthra-
cycline therapy; this may progress to heart failure with preserved
left ventricular ejection fraction (LVEF) and eventually to heart
failure with reduced EF. Endomyocardial biopsies performed on
patients exposed to anthracyclines have demonstrated ultrastruc-
tural changes such as vacuolization, myofibrillar disorganiza-
tion, and myocyte necrosis, even in the absence of overt clinical
symptoms (8, 9).
The dose-dependent relationship of anthracyclines and car-
diotoxicity has been well-characterized since the late 1970s. In a
retrospective analysis of 4018 patients with a variety of tumors who
received doxorubicin, the number of patients who developed CHF
was 3% at a cumulative doxorubicin dose of 400 mg/m2, 7% at a
cumulative dose of 550 mg/m2, and 18% at a dose of 700 mg/m2
(4). However, another analysis of doxorubicin-associated car-
diotoxicity revealed an even higher incidence of CHF at 26% with a
cumulative dose of 550 mg/m2 (10). These authors also found that
CHF occurred at total cumulative doses of <300 mg/m2, although
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this was relatively infrequent. Based on these observations, it is
generally recommended that the cumulative dose of doxorubicin
be limited to 400–450 mg/m2 in adults (see Table 1).
While cumulative dose remains the most significant risk factor
for the development of cardiotoxicity, other risk factors include
older age, radiation therapy, concomitant chemotherapy, and fac-
tors that may predispose to cardiovascular disease such as hyper-
tension and diabetes (4, 10–13). However, there is great variability
in patient susceptibility to cardiotoxicity. In the analysis by Von
Hoff, five patients received over 1000 mg/m2 of doxorubicin and
did not develop clinical cardiotoxicity, while others developed
CHF at much lower cumulative doses (4). Genetic polymorphisms
may account at least in part for some of the differences in suscep-
tibility, although studies performed in the pediatric population
have yielded conflicting results (14, 15).
MECHANISM OF ANTHRACYCLINE-INDUCED CARDIOTOXICITY
Cardiac myocytes have limited regenerative capabilities and thus
are especially susceptible to irreversible damage. The mechanism
by which anthracyclines induce cardiotoxicity has been a topic of
great debate and multiple hypotheses have been proposed. Until
recently the most widely accepted explanation has been the oxida-
tive stress model whereby generation of reactive oxygen species
(ROS) by redox cycling and iron–anthracycline complexes leads
to myocyte damage. However, this hypothesis has been called
into question given the failure of antioxidants such as vitamin
E, coenzyme Q10, and N -acetylcysteine and iron chelators such
a deferasirox to confer a cardioprotective effect in the clinical
setting (16–19).
More recently, investigators from MD Anderson Center pro-
posed an alternate explanation for anthracycline-induced car-
diotoxicity via the topoisomerase (Top) 2b enzyme (20). Anthra-
cycline binding to Top2 is a well-established mechanism of cel-
lular damage and antitumor activity. Top2a is overexpressed in
cancer cells but is absent in normal cells, whereas Top2b is
expressed only in normal cells, including cardiac myocytes. Using
a mouse knockout model, the researchers demonstrated that
cardiomyocyte-specific deletion of Top2b conferred protection
against doxorubicin-induced DNA damage, mitochondrial dys-
function and generation of ROS. In addition, mice lacking the
Top2b gene in cardiac muscle did not develop progressive heart
failure, whereas those with intact Top2 showed a decrease in EF
after doxorubicin exposure. Based on these findings, the inves-
tigators are now evaluating the utility of a Top2 blood test in
predicting sensitivity to doxorubicin-induced cardiac toxicity. If
the Top2 hypothesis is confirmed,one potential alternative to avoid
doxorubicin-induced cardiotoxicity could be to develop Top2a-
specific anthracyclines that would have maximum antitumor
activity without causing cardiotoxicity.
CARDIOPROTECTANTS
Several strategies have been used in an attempt to minimize
anthracycline-induced cardiotoxicity. Dexrazoxane is a cardio-
protective agent that is currently indicated for reducing the inci-
dence and severity of cardiomyopathy associated with doxorubicin
administration in patients with metastatic breast cancer, who have
















2.2a 3% at 400 mg/m2
7% at 550 mg/m2







5.1b 5% at 400 mg/m2
16% at 500 mg/m2
26% at 550 mg/m2
48% at 700 mg/m2
aBased on clinical signs and symptoms of CHF.
bProtocol definition of CHF included two or more of the following: cardiomegaly on
chest X-ray; basilar rales; S3 gallop; or paroxysmal nocturnal dyspnea, orthopnea,
or significant dyspnea on exertion.
received a cumulative doxorubicin dose of 300 mg/m2 and who
will continue to receive doxorubicin therapy to maintain tumor
control. Multiple studies have demonstrated a cardioprotective
effect when this agent is used during anthracycline treatment for
advanced breast cancer (21–25). In all of these studies, patients
who received dexrazoxane had a decreased incidence of CHF
compared to those who did not receive the drug. Yet despite
these consistent positive findings, the use of dexrazoxane has
not been widely adopted. This is due in part to the suggestion
from a single study that dexrazoxane may lower response rates,
although there was no impact on time to progression (TTP) or
overall survival (OS) seen in that trial (23). This finding has
not been seen in other studies, and a meta-analysis of five ran-
domized trials (n= 818) showed that there was no difference in
response rates between control patients and patients receiving
dexrazoxane (26).
The mechanism by which dexrazoxane is thought to confer
cardioprotection has not been fully elucidated. By binding to the
anthracycline–iron complex and removing iron, dexrazoxane may
prevent free radical-induced lipid peroxidation of mitochondrial
membranes and endoplasmic reticulum (27, 28). However, this
theory of iron chelation does not fully explain the cardioprotec-
tive mechanism of the drug given the observation that deferasirox,
an efficient iron-chelating agent that has been shown to enter
myocytes and displace iron from the anthracycline-iron complex,
is unable to protect myocytes from doxorubicin damage (19, 28).
An alternate hypothesis involves the ability of dexrazoxane to pre-
vent anthracycline binding to Top2. As discussed above, when
doxorubicin binds to Top2b in cardiac myocytes, it leads to DNA
damage, activation of the apoptotic pathway, and induction of
transcriptome change that leads to generation of ROS. Dexrazox-
ane binds to both Top2a and Top2b, thereby preventing anthra-
cycline binding of Top2 and consequent doxorubicin-induced
cell death (29). This hypothesis is supported by the observa-
tion that ICRF 161, an analog of dexrazoxane with iron-chelating
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properties but lacking activity against Top2, is unable to confer
cardioprotection in rat models (30).
REDUCING THE RISK OF TOXICITY
Other strategies to reduce cardiotoxicity have also been evaluated.
Continuous infusion of doxorubicin is associated with less cardiac
toxicity than bolus infusion (31, 32). However, this schedule is less
convenient and hence is not a widely used strategy.
4′-Epidoxorubicin, or epirubicin, is an analog of doxorubicin
with equivalent efficacy and less cardiotoxicity on a milligram
to milligram comparison (33–36). In a prospective randomized
comparison of doxorubicin and epirubicin in patients with breast
cancer, epirubicin was associated with a longer median dura-
tion of response at 11.9 months compared to 7.1 months with
doxorubicin. The cumulative doses at which CHF occurred was
1134 mg/m2 with epirubicin compared to 492 mg/m2 with dox-
orubicin (15). In a meta-analysis of 13 studies comparing dox-
orubicin with epirubicin, the majority of which included women
with advanced or metastatic breast cancer, epirubicin was associ-
ated with a significantly decreased risk of clinical cardiotoxicity,
subclinical cardiotoxicity, and any cardiac event compared to
doxorubicin (32). Epirubicin-induced cardiotoxicity is also dose-
dependent (37), and the United States Food and Drug Admin-
istration (FDA) recommends a maximum cumulative dose of
900 mg/m2. However, in an analysis of 1097 patients, the safe
maximum cumulative dosage was found to be lower when risk
factors such as age, radiation, and underlying cardiac risk factors
were taken into consideration (38).
Altering the pharmacokinetic and pharmacodynamic profile
of doxorubicin via liposome encapsulation has been an extremely
effective strategy to minimize cardiotoxicity and maximize effi-
cacy (39). One formulation of liposomal doxorubicin (Myocet)
has polyethylene glycol embedded in the lipid layers, allowing the
drug to stay in the liposome until it reaches the target tumor site
(40). It is thought that the small size of the liposomes enables the
drug to penetrate the compromised vasculature of tumors, allow-
ing preferential delivery of the drug to the target tumor. Pegylation
protects the liposome from uptake by the reticular-endothelial sys-
tem, thereby increasing blood circulation time. Pegylated liposo-
mal doxorubicin (PLD [Doxil/Caelyx]) has a half-life of 73.9 h; this
prolonged circulation time enables greater uptake of the drug by
tumor. A phase III trial was conducted in 509 women with metasta-
tic breast cancer to compare the efficacy and safety of PLD and
conventional doxorubicin in the first-line setting. Response rates,
progression-free survival (PFS), and OS were similar in both arms;
however, overall risk of cardiotoxicity was significantly higher with
conventional doxorubicin than with PLD (P < 0.001, HR= 3.16)
(41). In a meta-analysis of four studies comparing liposomal dox-
orubicin with conventional doxorubicin for the treatment of breast
cancer or multiple myeloma, liposomal doxorubicin appeared to
have similar efficacy to doxorubicin but was associated with sig-
nificantly less risk of clinical or subclinical cardiotoxicity or any
cardiotoxic event (32).
TRASTUZUMAB-INDUCED CARDIOTOXICITY
Approximately 20–25% of breast cancers overexpress the human
epidermal growth factor receptor-2 (HER2 or ErbB2) (42, 43).
Such overexpression has been associated with more aggressive
tumor biology, altered responsiveness to therapy, and poor clini-
cal outcome including shortened survival (44). The development
of trastuzumab, a humanized monoclonal antibody that targets
the HER2 receptor, has been a major advance in the treatment of
HER2-positive breast cancer.
The pivotal trial that led to the FDA approval of trastuzumab
in 1998 enrolled 469 patients with previously untreated HER2-
positive metastatic breast cancer who were randomized to
receive chemotherapy alone (consisting of an anthracycline plus
cyclophosphamide in anthracycline-naïve patients or paclitaxel in
patients previously treated with an anthracycline) or chemother-
apy plus trastuzumab (45). The combination of chemotherapy
plus trastuzumab resulted in an improved response rate (50
versus 32%; P < 0.001), TTP (median 7.4 versus 4.6 months;
P < 0.001), and OS (median 25.1 versus 20.3 months; P = 0.046)
when compared with chemotherapy alone.
An unanticipated serious adverse event that emerged from
the study was cardiac dysfunction. The rates of cardiac tox-
icity in patients randomized to doxorubicin and cyclophos-
phamide (AC) with trastuzumab versus AC alone were 27 and
8%, respectively, and the rates of cardiac dysfunction in patients
who received paclitaxel and trastuzumab versus paclitaxel alone
were 13 and 1%, respectively. The incidence of New York Heart
Association (NYHA) class III or IV heart failure was highest
among patients receiving AC plus trastuzumab: 16%, compared
with 3% for patients receiving AC alone, 2% for paclitaxel plus
trastuzumab, and 1% for paclitaxel alone. Because the combi-
nation of trastuzumab plus doxorubicin resulted in unaccept-
ably high rates of cardiac toxicity, these agents are generally not
administered concurrently unless within the context of a clinical
trial.
As a result of the above findings, the major adjuvant tri-
als allowed only sequential administration of anthracyclines and
trastuzumab (46–54). In addition, patients with abnormal car-
diac function were excluded, the cumulative doxorubicin dose was
limited to 300 mg/m2, and strict cardiac monitoring was man-
dated. The incidence of severe cardiotoxicity (NYHA class III or
IV) in the adjuvant trials was modest: 0–4.1% in trastuzumab-
treated patients versus 0–1.3% in the non-trastuzumab population
(see Table 2). A meta-analysis of the five major adjuvant trials
reported a 2.5-fold higher risk of cardiotoxicity with trastuzumab
(54). Not surprisingly, a higher incidence of cardiotoxicity has
been noted in patients also treated with anthracyclines and in
patients who received a longer duration of trastuzumab in the
adjuvant setting (55, 56).
Risk factors for the development of trastuzumab-related
cardiotoxicity include prior or concurrent anthracycline use,
age >50 years, pre-existing cardiac dysfunction, use of anti-
hypertensive medication, and higher body mass index (56–59).
The risk appears to be highest when trastuzumab is administered
concurrently with anthracyclines, mostly when the cumulative
dose of doxorubicin exceeds 300 mg/m2 (60). Cumulative doses
up to 180 mg/m2 may in fact be safe to administer concurrently
with trastuzumab (61), although there are no data demonstrating
that such an approach would be more effective than sequential
administration.
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Table 2 | Incidence of trastuzumab-associated cardiac events in adjuvant breast cancer trials.
Trial Number of patients
in analysis
Treatment arm Incidence of
cardiac events (%)
Definition of cardiac event
NSABP B-31 (46, 51) 814 AC→P 0.8 NYHA class III/IV CHF or
possible/probable cardiac death850 AC→PH 4.1
NCCTG N9831 (52) 664 AC→P 0.3 Symptomatic CHF or
probably/definite cardiac death710 AC→P→H 2.8
570 AC→PH 3.3
HERA (53) 1744 Chemotherapy 0.1 NYHA class III/IV CHF with decrease
in LVEF ≥10% from baseline to LVEF
<50%; or cardiac death
1682 Chemotherapy+1 year of Trastuzumab 0.8
1673 Chemotherapy+2 years of Trastuzumab 1.0
BCIRG 006 (48) 1073 AC→T 0.7 NYHA class III/IV CHF
1074 AC→TH 2
1075 TCH 0.4
FinHer (95) 116 Chemotherapy 1.7 Symptomatic heart failure
115 Chemotherapy+Trastuzumab 0.9
AC, doxorubicin+ cyclophosphamide; P, paclitaxel; H, trastuzumab; T, docetaxel; C, carboplatin.
MECHANISM OF TRASTUZUMAB-INDUCED CARDIOTOXICITY
Unlike anthracycline-induced cardiotoxicity, trastuzumab-related
cardiotoxicity is classified as Type II and is clinically and mechanis-
tically distinct (62). Type II cardiotoxicity is not dose-dependent,
is highly reversible, and is not associated with ultrastructural
changes. This was demonstrated in a study of 38 patients with
suspected trastuzumab-related cardiotoxicity, all of whom had
received prior doxorubicin (63). Mean LVEF prior to initiation
of trastuzumab was 61%, decreased to 43% after trastuzumab,
and increased to 56% after withdrawal of trastuzumab. Increases
of LVEF were seen in 37 out of the 38 patients and mean time
to recovery was 1.5 months. Six of the patients recovered with-
out medical treatment. Nine patients underwent endomyocardial
biopsy and the ultrastructural changes typical of anthracycline
damage were not seen. The absence of such changes on biopsy
demonstrates that the mechanism by which trastuzumab induces
cardiac dysfunction is different from anthracyclines and is likely
due to myocardial stunning or hibernation.
The pathogenesis of trastuzumab cardiotoxicity is not com-
pletely understood. The HER2 signaling pathway is essential for
cardiac development and function (64), and mouse models lacking
HER2 exhibit multiple characteristics of dilated cardiomyopathy,
including chamber dilation, wall thinning, and decreased contrac-
tility (65). HER2 signaling is upregulated in animal models when
the myocardium is under stress (66) Binding of trastuzumab to
HER2 is thought to disrupt HER2-HER4 heterodimerization, thus
disabling the protective mechanisms in the cardiac myocyte that
are essential during exposure to adverse conditions or cardiac tox-
ins (67). This hypothesis is consistent with the observation that
increased cardiac toxicity is seen when trastuzumab is used in
association with anthracyclines. Indeed, HER2-deficient cardiac
myocytes are more susceptible to anthracycline-induced dam-
age (65, 68). Activation of HER2 signaling by neuregulin-1 has
been shown to improve cardiac myocyte function and survival,
and upregulation of this pathway in the heart may be a potential
therapeutic approach (69).
CLINICAL USE OF TRASTUZUMAB
The risk of cardiac toxicity with trastuzumab needs to be con-
sidered within the clinical context. In the metastatic setting, the
benefits conferred by the addition of trastuzumab often outweigh
the potential cardiac risks. On the other hand, in the early-stage
setting, a significant number of patients will be cured with local
therapy alone and may not in fact require adjuvant systemic ther-
apy. However, since it is not currently possible to identify these
patients, adjuvant therapy is offered to many who may not in fact
derive benefit. One must therefore be especially judicious when
selecting an adjuvant regimen, which may expose a patient to
unnecessary toxicities, including CHF.
Because of the increased risks of cardiac toxicity seen with both
the anthracyclines and trastuzumab, there has been much interest
in the development of non-anthracycline-containing trastuzumab
regimens. Of the pivotal adjuvant trastuzumab trials, Breast Can-
cer International Research Group (BCIRG) 006 was the only
one to include a non-anthracycline-containing arm (48). In this
study, 3222 patients with HER2+ breast cancer were random-
ized to receive AC followed by docetaxel (AC-T), AC-T plus
trastuzumab initiated concurrently with docetaxel (AC-TH), or
docetaxel+ carboplatin+ trastuzumab (TCH). No significant dif-
ferences in DFS and OS were found between the two trastuzumab
regimens. However, there were significant differences in the inci-
dence of CHF: 0.4% in the AC-T arm, 2.0% in the AC-TH arm,
and 0.7% in the TCH arm. In addition,AC-TH was associated with
a significantly increased risk of persistent decline in EF at 4 years
compared to TCH.
A recent retrospective population-based cohort study evalu-
ated the long-term risk of heart failure (in this case defined
as hospitalization or two ambulatory visits within 12 months)
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associated with adjuvant trastuzumab and chemotherapy (70).
Women included in this study were diagnosed with early-stage
breast cancer between 2003 and 2009. Those with metastatic
breast cancer or a pre-existing diagnosis of heart failure were
excluded. 19,074 women treated with chemotherapy were iden-
tified, of whom 18% also received adjuvant trastuzumab. After a
median follow-up of 5.9 years, investigators found that adjuvant
trastuzumab was associated with an increased risk of heart fail-
ure (5.3 versus 2.6%, P < 0.0001). However, the increased risk was
seen only within the first 1.5 years of treatment (HR= 5.77, 95%
CI 4.38–7.62,p= 0.0004); thereafter, there was no difference in the
risk of developing CHF between women treated with trastuzumab
plus chemotherapy and those treated with chemotherapy alone
(HR= 0.87, 95% CI 0.57–1.33, p= 0.53). These data are reas-
suring in that the risk of trastuzumab-associated cardiotoxicity
appears to be limited to the period of active treatment.
No evidence-based guidelines exist for cardiac monitoring
while on trastuzumab therapy. The FDA-approved manufacturer’s
package insert recommends that a baseline assessment of car-
diac function be performed prior to the initiation of therapy and
LVEF measurements should be repeated every 3 months during
and upon completion of therapy (71). If trastuzumab is withheld
for significant cardiac dysfunction, LVEF measurement should be
repeated at 4-week intervals. In the adjuvant setting it is rec-
ommended that LVEF be assessed every 6 months for at least
2 years following completion of therapy. In the metastatic setting,
however, symptom-triggered evaluation of LVEF may be more
appropriate given the risk-benefit ratio.
Trastuzumab should be held for 4 weeks if LVEF declines≥16%
from baseline or if there is a≥10% decrease in LVEF from baseline
to below the lower limit of normal. Treatment may be restarted
if LVEF returns to normal within 4–8 weeks. Trastuzumab should
be discontinued in the presence of symptomatic heart failure.
CARDIOVASCULAR RISK WITH OTHER HER2-DIRECTED
THERAPIES
Lapatinib is a reversible small tyrosine kinase inhibitor that targets
both the epidermal growth factor receptor (EGFR or HER1) and
HER2. It is indicated for use in combination with capecitabine for
the treatment of metastatic HER2+ breast cancer after progres-
sion on an anthracycline, taxane and trastuzumab. In the phase III
trial that led to its approval, asymptomatic declines in EF occurred
in 4 of 164 (2.4%) of patients receiving lapatinib plus capecitabine
versus 1 of 152 (0.7%) of patients receiving capecitabine alone. All
four patients who experienced a cardiac event on lapatinib recov-
ered and there were no symptomatic events (72) (see Table 3).
It is important to note that the patients in this trial were highly
selected as all had previously received trastuzumab and cardiac
dysfunction was an exclusion criterion.
In a retrospective analysis of 3689 patients with various solid
tumor types treated with lapatinib, only 1.6% of patients devel-
oped a cardiac event (73). Similar rates of cardiotoxicity were
noted in patients who were pretreated with anthracyclines or
trastuzumab compared to those who were not pretreated. Most of
the cardiac events were usually asymptomatic and reversible, indi-
cating a Type II cardiac toxicity. More recently, data were presented
from the Adjuvant Lapatinib and/or Trastuzumab Treatment Opti-
mization (ALTTO) trial in which patients with early-stage HER2+
breast cancer were randomized to receive adjuvant chemotherapy
with trastuzumab, chemotherapy with concurrent trastuzumab
and lapatinib, or chemotherapy with sequential trastuzumab and
lapatinib (74). The incidence of NYHA Class III/IV heart failure
was <1% in all arms, with 97% of all patients having received an
anthracycline.
Pertuzumab is a humanized monoclonal antibody that binds
to HER at its dimerization subdomain. When combined with
trastuzumab and docetaxel in the first-line setting for metasta-
tic HER2+ breast cancer, there was an improvement in PFS and
OS compared to trastuzumab and docetaxel (75). Interestingly,
in a cardiac analysis of the trial, left ventricular dysfunction
was numerically higher in the control arm (8.3 versus 4.4% for
all grades). Declines in EF of at least 10% from baseline to
<50% occurred in 6.6 versus 3.8% of patients in the placebo
and pertuzumab arms, respectively (76). Thus the combination
of both antibodies did not increase the risk of cardiac adverse
events.
Table 3 | Incidence of cardiac events with other HER2-directed therapies.
Trial Number of patients
in analysis
HER2-directed therapy Incidence of
cardiac events (%)
Definition of cardiac event
Geyer et al. (72) 161 Capecitabine 0.7 Symptomatic decline in LVEF or
decrease ≥20% from baseline to
below institution’s lower limit of normal
163 Lapatinib plus Capecitabine 2.4
ALTTO (74) 2097 Trastuzumab alone 0.86 NYHA Class III/IV CHF or cardiac death
2091 Trastuzumab followed by Lapatinib 0.25
2093 Trastuzumab concurrent with Lapatinib 0.97
CLEOPATRA (76) 397 Trastuzumab+docetaxel plus placebo 6.6 LVEF decline to <50% with decrease
≥10% from baseline407 Trastuzumab+docetaxel plus Pertuzumab 3.8
EMILIA (77) 445 Lapatinib + capecitabine 1.6 LVEF decline to <50% with decrease
≥15% from baseline481 T-DM1 1.7
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Ado-trastuzumab emtansine (T-DM1) is an antibody-drug
conjugate which combines trastuzumab with the cytoxic agent
emtansine. The EMILIA trial randomized 991 patients with
advanced breast cancer previously treated with trastuzumab and
a taxane to TDM-1 versus lapatinib plus capecitabine. Results
demonstrated an improvement in PFS and OS with T-DM1 com-
pared to lapatinib plus capecitabine. Cardiotoxicity was 1.7% with
T-DM1 versus 1.6% in the other arm (77).
CARDIOVASCULAR RISK WITH BEVACIZUMAB
In recent years, there has been considerable interest in the use of
antiangiogenic agents for the treatment of various cancers. Beva-
cizumab, a monoclonal antibody targeting vascular endothelial
growth factor (VEGF), was initially granted accelerated approval
in 2008 for metastatic breast cancer based on impressive results in
the first-line setting when combined with paclitaxel (78). How-
ever, while subsequent trials in the first-line metastatic setting
confirmed a benefit in PFS, the magnitude of benefit was small,
and no OS benefit was shown in any of the studies (79, 80). Three
subsequent large adjuvant studies also failed to demonstrate a ben-
efit in DFS or OS and consequently the FDA withdrew approval
for bevacizumab in 2011. Nevertheless, as this agent is still used
widely in other types of solid tumors, familiarly with its potential
cardiac toxicities is important.
A meta-analysis of 5 randomized trials in metastatic breast
cancer showed a statistically significant increased risk in grade
3 or higher hypertension (9.71 versus 0.64%, OR= 12.76) and left
ventricular dysfunction (1.73 versus 0.78%, OR= 2.25) in patients
treated with bevacizumab compared to those who did not receive
the drug (81). Similar increased risks were also seen in other stud-
ies, including the three adjuvant trials (82–84). The mechanism
of bevacizumab-induced hypertension is not known but may be
related to nitric oxide: VEGF is thought to increase production
of nitric oxide, resulting in vasodilation (85). Inhibition of nitric
oxide by bevacizumab therefore leads to vasoconstriction and con-
sequent hypertension. The mechanism of CHF is also unclear,
but the development of secondary hypertension itself could be a
contributing factor.
BIOMARKERS
Current methods for detecting cardiotoxicity rely on evaluation
of LVEF by either echocardiography or Multiple Gated Acqui-
sition (MUGA) scan. However, by the time a decrease in EF is
detected there has already been considerable myocardial damage.
There is therefore a need to develop biomarkers that enable the
early identification of cardiac deterioration. Such a strategy would
allow for the implementation of preventive measures prior to the
development of functional impairment.
Cardiac troponins I (cTnI) and T (cTnT) are sensitive and spe-
cific biomarkers of myocardial damage, whereas B-type natriuretic
peptide (BNP) is a marker of volume overload. These markers
have been studied as potential indicators of treatment-related
cardiotoxicity.
In a study of 204 patients with a variety of malignancies receiv-
ing high-dose chemotherapy, investigators measured levels of cTnI
in the plasma after every cycle. Patients were divided into troponin
positive (cTnI+) and troponin negative (cTnI−) groups. In the
cTnI− group, LVEF decreased transiently after chemotherapy,
with a nadir after 3 months, but later recovered. On the other
hand, patients in the cTnI+ group sustained greater reductions
in LVEF, and the declines persisted even at the end of 7 months’
follow-up (86). The same group of investigators also evaluated
the significance of persistent elevations in cTnI+ and found that
patients treated with high-dose chemotherapy who had persis-
tent increases in cTn1 had a higher incidence of cardiac toxicity
(85%) compared to patients with transient increases (37%) or who
had no elevation in cTn1 (1%) (87). Similarly, persistent proBNP
elevation following chemotherapy has been associated with sig-
nificantly lower LVEF (88). Given the heterogeneity of the study
populations, however, definitive conclusions cannot be drawn at
this time and more research is needed to determine whether these
findings can be replicated.
TREATMENT AND PREVENTION OF LV DYSFUNCTION
Beta-blockers and angiotensin converting enzyme (ACE)
inhibitors are standard treatments that have been shown to
improve outcomes in patients with heart failure from a variety of
etiologies. Treatment of cardiac dysfunction resulting from anti-
neoplastic therapy follows the general cardiology guidelines for
heart failure, although this practice seems to be based primarily
on extrapolation rather than on evidence specifically addressing
heart failure in the cancer population.
In a study of 201 consecutive patients with anthracycline-
induced CHF with LVEF ≤45%, enalapril and, when tolerated,
carvedilol were initiated as soon as LVEF impairment was detected
(89). The investigators found that time elapsed from the end of
chemotherapy to the start of heart failure therapy was a crucial
variable for recovery of cardiac function. Among patients treated
within 2 months after the end of chemotherapy, 64% had a com-
plete recovery of LVEF. After 2 months, however, the percentage of
patients decreased, with no complete recovery seen after 6 months.
There has been significant interest evaluating the role of beta-
blockers and ACE inhibitors as prophylactic agents in patients
who are at risk of developing treatment-related cardiotoxicity. In a
study that enrolled 50 patients receiving anthracycline therapy for
a variety of cancers, patients were randomized to receive prophy-
lactic carvedilol or placebo (90). Baseline LVEF was similar in both
groups prior to initiation of chemotherapy. At 6 months of follow-
up, one patient in the carvedilol group had EF< 50% compared to
five patients in the control group. The mean EF in the carvedilol
group remained unchanged at the end of follow-up (70.5 ver-
sus 69.7%) but was significantly lower in the control group (68.9
versus 52.3%). However, there were some discrepancies in the
reported anthracycline doses used in the study and caution should
therefore be exercised when interpreting these data.
In a trial by Cardinale et al., 114 patients receiving high-dose
chemotherapy and deemed at high risk for cardiotoxicity based
on troponin I elevation were randomized to receive the ACE
inhibitor enalapril or not (91). Enalapril was started 1 month
after chemotherapy and continued for 1 year. The primary end-
point was an absolute decrease of >10% in LVEF, with a decline
below the lower limit of normal. Forty-three percent of patients in
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the control arm met the primary endpoint, compared to none
in the treatment group (P < 0.001). These results suggest that
in patients with evidence of early cardiac damage as measured
by elevated troponin I values, early institution of ACE inhibitor
therapy may prevent the progression of cardiac toxicity. The pre-
vention of cardiac dysfunction during adjuvant breast cancer ther-
apy (PRADA) trial is an ongoing randomized, placebo-controlled
study evaluating the role of beta-blockers and ACE inhibitors
in preventing cardiac dysfunction during adjuvant breast cancer
therapy (92).
LACK OF CLINICAL GUIDELINES
Unfortunately, the American College of Cardiology and the Amer-
ican Heart Association have not provided any guidelines for the
detection, prevention, monitoring, or treatment of cardiotoxic-
ity from antineoplastic therapy. All patients receiving potentially
cardiotoxic anticancer drugs are considered candidates for Stage
A heart failure, meaning they are at increased risk of develop-
ing cardiac dysfunction (93). The European Society of Medical
Oncology has published a comprehensive set of clinical prac-
tice guidelines for the management of patients with cardiotoxicity
from chemotherapy, targeted agents, and radiation (94). A similar
consensus statement from the major American cardiology soci-
eties would be extremely helpful to practicing clinicians to ensure
maximal anticancer benefits from therapy with minimal cardiac
complications.
CONCLUSION
While much progress has been made in the treatment of breast
cancer, cardiac complications resulting from therapy remain a sig-
nificant concern. Both anthracyclines and novel targeted agents
can inflict cardiac damage, although the mechanisms by which
they do so and their clinical manifestations appear to be distinct.
The challenge for the future will be to develop methods for early
detection of cardiac dysfunction, identify strategies for prevention
and treatment of cardiotoxicity, and establish clinical guidelines
for practicing physicians. Many questions remain unanswered,
and ongoing research and collaboration between oncologists and
cardiologists are needed to ensure optimal efficacy and safety of
current and future anticancer agents.
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